OncLive

OncLive has been a member of Linktree for 1 year and joined in February 2025. The social media accounts linked to from OncLive are: Facebook, Instagram, YouTube, LinkedIn, X, Bluesky. Besides social media accounts, onclive has populated their site with Breast Cancer Briefing - Episode 6, FDA Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC | OncLive, Oncology Conferences to Watch in the Second Half of 2025, Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer, FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer | OncLive, Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress | OncLive, OncLive - Clinical Oncology News, Cancer Expert Insights, From Growing Survivorship Programs to Practicing Self-Care: A Day in the Life With Oncologist Alicia Morgans, MD, MPH, ‎OncLive Insider - Apple, 4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation, OncLive Insider - Android, FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS, 🎙 Podcasts 🎙| Clinical Oncology News & Insights | OncLive, SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting, Try Out Scout!, FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas, FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025, Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting, Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer | OncLive, Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC | OncLive, Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025 | OncLive, FDA Approves 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer, Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies, Cellular Therapies Begin to Make Their Mark in Solid Tumors, Rising Incidences, Misconceptions, and Unmet Needs Warrant Awareness for Appendix Cancer, OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology, FDA’s Published CRLs Deliver Insight Into the Drug Approval Process, FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations, Minimally Invasive Surgery and Multidisciplinary Collaboration Improves Recovery Time in Lung Cancer, FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma, Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic, FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations, FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC, Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer, FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma, Subscribe to OncLive’s conference emails, Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List, FDA Grants Accelerated Approval to Dato-DXd for EGFR+ NSCLC, Hematologists Highlight Notable Insights From the 2025 EHA Congress, ‎OncLive Insider App, OncLive App Info, FDA Approves Taletrectinib for ROS1+ Advanced NSCLC, FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC, FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC, FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma, Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress, ASCO Annual Meeting, BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer, FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC, FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC, Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting, Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting, Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting, Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025, Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting, Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences, Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting, Oncology Experts Preview Top Abstracts From AUA 2025, American Urological Association Annual Meeting, OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025, AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs, FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma, OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025, Anal Cancer Awareness Day Q&A.